Top

Published in:

Open Access 01-03-2016 | Original Article

Effectiveness of botulinum toxin injection in the treatment of de novo OAB symptoms following midurethral sling surgery

Authors: Pawel Miotla, Konrad Futyma, Rufus Cartwright, Michal Bogusiewicz, Katarzyna Skorupska, Ewa Markut-Miotla, Tomasz Rechberger

Published in: International Urogynecology Journal | Issue 3/2016

Abstract

Introduction and hypothesis

Intravesical onabotulinumtoxinA (Botox®) is effective for idiopathic overactive bladder (OAB) symptoms. Our primary objective was to compare the efficacy of onabotulinumtoxinA for women with de novo OAB after midurethral sling (MUS) surgery and women with idiopathic OAB.

Methods

Women enrolled in this prospective study had idiopathic (n = 53) or de novo (n = 49) OAB symptoms after MUS, with at least one episode of urgency urine incontinence per day. OnabotulinumtoxinA (100 U) was administered in 20 intradetrusor injections. Postvoid residual volumes were checked at 2, 4 and 12 weeks. Participants completed a 3-day bladder diary and the King’s Health Questionnaire (KHQ) before and 12 weeks after treatment.

Results

After 12 weeks, 22 patients (41.5 %) in the idiopathic OAB and 19 patients (38.8 %) in the de novo OAB groups were completely dry. OnabotulinumtoxinA injections had a significant benefit within both groups (p <0.001) to decrease both the daily numbers of voids (−2.39 and −2.0) and incontinence episodes (−1.38 and −1.44), with no significant difference between groups. We observed an increase of mean voided volume of >90 ml in both groups. Urinary retention was observed in four patients.

Conclusions

We observed similar improvement in OAB symptoms after intravesical onabotulinumtoxinA injections within both groups. The rates of retention and requirement for catheterization even for women with a prior MUS were acceptable. These observational data provide evidence that onabotulinumtoxinA can effectively treat patients with OAB following stress urinary incontinence surgery.

Raman SV, Raker CA, Sung VW (2014) Concomitant apical prolapse repair and incontinence procedures: trends from 2001–2009 in the United States. Am J Obstet Gynecol 211:222.e1–222.e5CrossRef

Wu JM, Matthews CA, Conover MM, Pate V, Jonsson Funk M (2014) Lifetime risk of stress urinary incontinence or pelvic organ prolapse surgery. Obstet Gynecol 123:1201–1206PubMedCentralCrossRefPubMed

Palva K, Nilsson CG (2011) Prevalence of urinary urgency symptoms decreases by mid-urethral sling procedures for treatment of stress incontinence. Int Urogynecol J22:1241–1247CrossRef

Petri E, Ashok K (2012) Complications of synthetic slings used in female stress urinary incontinence and applicability of the new IUGA-ICS classification. Eur J Obstet Gynecol Reprod Biol 165:347–351CrossRefPubMed

Serati M, Ghezzi F, Cattoni E et al (2012) Tension-free vaginal tape for the treatment of urodynamic stress incontinence: efficacy and adverse effects at 10-year follow-up. Eur Urol 61:939–946CrossRefPubMed

Lee JK, Dwyer PL, Rosamilia A, Lim YN, Polyakov A, Stav K (2013) Which women develop urgency or urgency urinary incontinence following midurethral slings? Int Urogynecol J 24:47–54CrossRefPubMed

Bogusiewicz M, Monist M, Gałczyński K, Woźniak M, Wieczorek AP, Rechberger T (2014) Both the middle and distal sections of the urethra may be regarded as optimal targets for 'outside-in' transobturator tape placement. World J Urol 32:1605–1611PubMedCentralCrossRefPubMed

Wang F, Song Y, Huang H (2009) Which placement of the tension- free vaginal tape is more important for urinary continence: midurethral position or bladder neck? Consideration from a case report. Int Urogynecol J Pelvic Floor Dysfunct 20:1277–1279CrossRefPubMed

Bogusiewicz M, Monist M, Stankiewicz A, Woźniak M, Wieczorek AP, Rechberger T (2013) Most of the patients with suburethral sling failure have tapes located outside the high-pressure zone of the urethra. Ginekol Pol 84:334–338PubMed

10.

Stewart WF, Corey R, Herzog AR et al (2001) Prevalence of overactive bladder in women: results from the NOBLE program. Int Urogynecol J 12:66

11.

Agarwal A, Eryuzlu LN, Cartwright R et al (2014) What is the most bothersome lower urinary tract symptom? Individual- and population-level perspectives for both men and women. Eur Urol 65:1211–1217PubMedCentralCrossRefPubMed

12.

Robinson D, Giarenis I, Cardozo L (2013) The management of overactive bladder refractory to medical therapy. Maturitas 75:101–104CrossRefPubMed

13.

Rechberger T, Kulik-Rechberger B, Miotła P, Wrobel A (2014) The new era in the pharmacological treatment of overactive bladder (OAB): mirabegron-a new selective beta3agonist. Ginekol Pol 853:214–219

14.

Serati M, Braga A, Sorice P, Siesto G, Salvatore S, Ghezzi F (2014) Solifenacin in women with de novo overactive bladder after tension-free obturator vaginal tape-is it effective? J Urol 191:1322–1326CrossRefPubMed

15.

Chapple C, Sievert KD, MacDiarmid S et al (2013) OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. Eur Urol 64:249–256CrossRefPubMed

16.

Fowler CJ, Auerbach S, Ginsberg D et al (2012) OnabotulinumtoxinA improves health-related quality of life in patients with urinary incontinence due to idiopathic overactive bladder: a 36-week, double-blind, placebo-controlled, randomized, dose-ranging trial. Eur Urol 62:148–157CrossRefPubMed

17.

Sievert KD, Chapple C, Herschorn S et al (2014) OnabotulinumtoxinA 100U provides significant improvements in overactive bladder symptoms in patients with urinary incontinence regardless of the number of anticholinergic therapies used or reason for inadequate management of overactive bladder. Int J Clin Pract 68:1246–1256PubMedCentralCrossRefPubMed

18.

Nitti VW, Dmochowski R, Herschorn S, EMBARK Study Group et al (2013) OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol 189:2186–2193CrossRefPubMed

Title: Effectiveness of botulinum toxin injection in the treatment of de novo OAB symptoms following midurethral sling surgery
Authors: Pawel Miotla
Konrad Futyma
Rufus Cartwright
Michal Bogusiewicz
Katarzyna Skorupska
Ewa Markut-Miotla
Tomasz Rechberger
Publication date: 01-03-2016
Publisher: Springer London
Published in: International Urogynecology Journal / Issue 3/2016
Print ISSN: 0937-3462
Electronic ISSN: 1433-3023
DOI: https://doi.org/10.1007/s00192-015-2839-x

At a glance: The STEP trials

Springer Medicine

Effectiveness of botulinum toxin injection in the treatment of de novo OAB symptoms following midurethral sling surgery

Abstract

Introduction and hypothesis

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Introduction and hypothesis

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2016

Risk of postoperative urinary tract infections following midurethral sling operations in women undergoing hysterectomy

Bladder symptoms and urodynamic observations of patients with endometriosis confirmed by laparoscopy

Is pretreatment cystometry important in predicting response to mirabegron in women with overactive bladder symptoms?

Robotic versus laparoscopic sacrocolpopexy for treatment of prolapse of the apical segment of the vagina: a systematic review and meta-analysis

Polyacrylamide hydrogel (Bulkamid®) for stress urinary incontinence in women: a systematic review of the literature

Preoperative vaginal estrogen and midurethral sling exposure: a retrospective cohort study